

**Category** : Study conduct  
**Title** : Serious Adverse Event (SAE) Documentation  
**SOP No.** : D 15/07  
**Date first effective:** 01 Jan 2025      **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

**Category:** Study conduct  
**Title:** Serious Adverse Event (SAE) Documentation.

**SOP No.:** D 15/07      **Total pages:** 12  
**Date first effective:** 01 Jan 2025      **Next Review date:** 31 Dec 2025


**Version:** 07

**SOP team:**

**Author:** Dr. Vinayak A.  
DM Resident


**Signature with date**   
30/Dec/2024

**Reviewer:** Dr. Mahesh Belhekar  
Associate Professor

**Signature with date**   
30/Dec/2024

**Dr. Mahesh N. Belhekar**  
Associate Professor  
Department of Clinical Pharmacology  
New MS Building, First Floor,  
Seth GS Medical College and KEM Hospital  
Acharya Donda Marg, Parel,  
Mumbai - 400 012, India

**Approved by:** Dr. Nithya Gogtay  
Professor and Head

**Signature with date**   
30/12/24

**Dr. Nithya Gogtay**  
Professor & Head  
Department of Clinical Pharmacology  
1<sup>st</sup> Floor, MS Building,  
Seth GS Medical College & KEM Hospital,  
Parel, Mumbai - 400 012.

**Category** : Study conduct  
**Title** : Serious Adverse Event (SAE) Documentation  
**SOP No.** : D 15/07  
**Date first effective:** 01 Jan 2025      **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

### Table of Contents

No.	Contents	Page No.
1	Purpose	3
2	Scope	3
3	Responsibility	3
4	Applicable rules, regulations, and guidelines	3
5	Reference to other applicable SOPs	4
6	Detailed instructions	4
7	Appendices	6
8	Abbreviations	11

**Category** : Study conduct  
**Title** : Serious Adverse Event (SAE) Documentation  
**SOP No.** : D 15/07  
**Date first effective:** 01 Jan 2025      **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

### **1. Purpose**

This standard operating procedure (SOP) describes the responsibilities of the study team for documenting a serious adverse event (SAE) from the time it is identified until all follow-up activities associated with its resolution have been completed.

### **2. Scope**

This SOP applies to all clinical studies involving human participants.

### **3. Responsibilities**

Principal investigator (PI), Co-Investigator (Co-I), Study Co-Ordinator, or any other appropriately qualified staff in the team, as delegated by the Principal Investigator, will be responsible for documenting serious adverse events.

### **4. Applicable rules, regulations, and guidelines**

- ICMR's Ethical Guidelines for Biomedical and Health research involving Human Participants, ICMR(2017) [http://www.icmr.nic.in/guidelines/ICMR\\_Ethical\\_Guidelines\\_2017.pdf](http://www.icmr.nic.in/guidelines/ICMR_Ethical_Guidelines_2017.pdf) (last accessed 20 Dec 2024)
- New Drugs and Clinical Trials Rules, 2019  
[https://cdsco.gov.in/opencms/export/sites/CDSCO\\_WEB/Pdf-documents/NewDrugs\\_CTRules\\_2019.pdf](https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/NewDrugs_CTRules_2019.pdf) (last accessed 20<sup>th</sup> Dec, 2024)
- Indian GCP Guidelines 2001  
[https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download\\_file\\_division.jsp?num\\_id=MzM5NQ==](https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MzM5NQ==) (last accessed 20<sup>th</sup> Dec, 2024)
- International Conference on Harmonization, Guidance on Good Clinical Practice ICH GCP E6 (R3)  
[https://database.ich.org/sites/default/files/ICH\\_E6%28R3%29\\_Step4\\_FinalGuideline\\_2025\\_0106.pdf](https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf) (Adopted on 06 January 2025)

**Category** : Study conduct  
**Title** : Serious Adverse Event (SAE) Documentation  
**SOP No.** : D 15/07  
**Date first effective:** 01 Jan 2025      **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

- Standard-Operating-Procedures of Institutional Ethics Committee, Seth GS Medical College and KEM Hospital, Mumbai  
[https://www.kem.edu/wp-content/uploads/2024/12/institutional-ethics-committee/Standard-Operating-Procedures \(SOPs\)V7-effective-from-9th-Dec-2024\\_.pdf](https://www.kem.edu/wp-content/uploads/2024/12/institutional-ethics-committee/Standard-Operating-Procedures%20(SOPs)V7-effective-from-9th-Dec-2024_.pdf) (last accessed 20<sup>th</sup> Dec, 2024)

## **5. Reference to other applicable SOPs**

- SOP No D 03/07: Responsibilities of the Study Team
- SOP No D 14/07: Adverse event monitoring, recording, and reporting.
- SOP No D 21/07: Contact and communication with sponsor
- Addendum to SOP for SAE Reporting

## **6. Detailed Instructions:**

### **6.1 Identify SAE**

A Serious Adverse Event (SAE) is defined as-  
Any untoward medical occurrence that at any dose:

- Results in death,
- Is life-threatening,
- Requires in-patient hospitalization or prolongation of existing hospitalization,
- Results in persistent or significant disability/incapacity, or
- Is a congenital anomaly/birth defect.
- Is a significant medical event.

### **6.2 Medical management of an SAE**

**6.2.1.** Appropriate medical management of the SAE by referring to the appropriate collaborating (or any other as applicable) department in the institute. Supportive measures

**Category** : Study conduct  
**Title** : Serious Adverse Event (SAE) Documentation  
**SOP No.** : D 15/07  
**Date first effective:** 01 Jan 2025      **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

should be immediately used as appropriate and are directed towards participant safety and well-being.

**6.2.2.** Participant will be followed up till complete resolution.

### **6.3 Documentation of an SAE**

- 6.3.1. Document the nature of the SAE, which includes onset, duration, progress, management, and outcome in the participant's source document/s.
- 6.3.2. Relatedness of the SAE to the clinical trial must be assessed by the PI and reported in the SAE form (Appendix 1 and 2)
- 6.3.3. The SAE reporting form of the Department (See Appendix 1) and the SAE assessment form along checklist of the IEC (see Appendix 2) should be used for documentation in case of academic studies.
- 6.3.4. The SAE assessment form and checklist of the IEC (see Appendix 2) and SAE form provided by sponsors (if any) have to be filled in case of pharma sponsored studies.
- 6.3.5. In case the sponsor does not have a form then the SAE reporting form of the department (Appendix 1) should be used for documentation.
- 6.3.6. Complete documentation should be done in the source documents and case record forms (CRFs).

### **6.4 Reporting of an SAE**

- 6.5.1. Inform the Sponsor, Licensing Authority and Chairperson of Ethics Committee within 24 hours using the SAE reporting form (Appendix 1).
- 6.5.2. For an SAE (causing Death/ other than death): PI have to send a detailed report (after due analysis) within 14 days of the occurrence of the SAE (death) to the IEC, Head of the Institution and Licensing Authority (Appendix 3).
- 6.5.3. SAE Reporting is to be done online on the SUGAM portal as per the CDSCO order dated March 2021. Refer to Addendum SOP for SAE Reporting for details.

**Category** : Study conduct  
**Title** : Serious Adverse Event (SAE) Documentation  
**SOP No.** : D 15/07  
**Date first effective:** 01 Jan 2025      **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

### **6.5 Compensation- medical management and if related further compensation**

6.6.1. Reimburse the participant for all expenses toward the medical management of the SAE in case of academic studies.

6.6.2. In the case of sponsored studies, compensation to the participant will be provided by the sponsor as recommended by the Licensing authority.

6.6.3. If there is a clinical trial related death, the nominee will be contacted by the PI/ designated study team member for compensation as per regulatory rules.

### **6.6 Further steps**

6.6.1. Various steps may be taken with respect to further use of the investigational product, comparator, or placebo (in the interest of participant safety). This decision may only be made by the PI and will be as prescribed in the protocol, for example,

- Discontinue the investigational product, comparator, or placebo (Dechallenge)
- Reduce the dose.
- If necessary, for the immediate medical care of the participant, break the drug blind after consultation with the sponsor.

## **7. Appendices:**

### **Appendix 1: Table V for SAE Reporting**

**Category** : Study conduct  
**Title** : Serious Adverse Event (SAE) Documentation  
**SOP No.** : D 15/07  
**Date first effective:** 01 Jan 2025      **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
 Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

<b>1.</b>	<b><u>Country (name of the country should be specified)</u></b>	
<b>2.</b>	<b><u>SAE report of death or other than death</u></b>	
<b>3.</b>	<b><u>Patient details</u></b>	
	<b><u>Initials and other relevant identifier [hospital or outpatient department (OPD) record number etc]</u></b>	
	<b><u>Gender</u></b>	
	<b><u>Age or date of birth</u></b>	
	<b><u>Weight</u></b>	
	<b><u>Height</u></b>	
<b>4</b>	<b><u>Suspected Drug (s)</u></b>	
	<b><u>Generic name of the drug</u></b>	
	<b><u>Indication(s) for which suspect drug was prescribed or tested</u></b>	
	<b><u>Dosage form and strength</u></b>	
	<b><u>Daily dose and regimen (specific units- e.g., mg, ml,</u></b>	

**Category** : Study conduct  
**Title** : Serious Adverse Event (SAE) Documentation  
**SOP No.** : D 15/07  
**Date first effective:** 01 Jan 2025      **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
 Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

	<b><u>mg/kg)</u></b>	
	<b><u>Route of administration</u></b>	
	<b><u>Starting date and time of day</u></b>	
	<b><u>Stopping date and time, or duration of treatment</u></b>	
<b><u>5</u></b>	<b><u>Other treatment (s)</u></b>	
	<b><u>Provide the same information for concomitant drugs (including non-prescription or over the counter OTC drugs) and non-drug therapies, as for the suspected drug(s)</u></b>	
<b><u>6</u></b>	<b><u>Details of serious adverse events</u></b>	
	<b><u>Full description of the event including body site and severity as well as the criterion (or criteria) for considering the report as serious. In addition to a description of the reported sign and symptoms, whenever possible describe a specific</u></b>	



**Category** : Study conduct  
**Title** : Serious Adverse Event (SAE) Documentation  
**SOP No.** : D 15/07  
**Date first effective:** 01 Jan 2025      **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
 Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

	<b><u>diagnosis for the event</u></b>	
	<b><u>Start date (and time) of the onset of event</u></b>	
	<b><u>Stop date (and time) or duration of event</u></b>	
	<b><u>Dechallenge and rechallenge information</u></b>	
	<b><u>Setting (e.g. hospital, outpatient clinic, home, nursing home)</u></b>	
7	<b><u>Outcome:</u></b>	
	<b><u>Information on recovery and any sequelae; results of specific tests or treatment that may have been conducted</u></b>	
	<b><u>For a fatal outcome cause of death and a comment on its possible relationship to the suspected event. Any post-mortem findings</u></b>	
	<b><u>Other information: anything relevant to facilitate assessment of the case, such as medical</u></b>	

**Category** : Study conduct  
**Title** : Serious Adverse Event (SAE) Documentation  
**SOP No.** : D 15/07  
**Date first effective:** 01 Jan 2025      **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
 Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

	<b><u>history including allergy drug or alcohol abuse, family history, findings from special investigations etc.</u></b>	
<b><u>8</u></b>	<b><u>Details about the investigator*</u></b>	
	<b><u>Name and address</u></b>	
	<b><u>Telephone number</u></b>	
	<b><u>Profession (Specialty)</u></b>	
	<b><u>Date of reporting the event to Central Licensing Authority</u></b>	
	<b><u>Date of reporting the event to ethics committee overseeing the site:</u></b>	
	<b><u>Signature of the investigator or Sponsor</u></b>	
	<b><u>Note: Information marked * must be provided</u></b>	

Category : Study conduct  
Title : Serious Adverse Event (SAE) Documentation  
SOP No. : D 15/07  
Date first effective: 01 Jan 2025      Review date: 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

### **Appendix 2: IEC Checklist and Serious Adverse Event Report Assessment Form**

SOP 11-B/V6.1 available at <https://www.kem.edu/sae-annexures>

### **Appendix 3: Timelines for reporting SAE**

PI shall report all serious and unexpected adverse events to the Licensing Authority, the Sponsor or his representative and the Ethics Committee within <b>24 hours</b> of their occurrence.
PI shall be forwarded the report of the SAE, after due analysis, to the Licensing Authority, the Chairman of the Ethics Committee, and the Head of the institution within <b>14 days</b> of the occurrence.
The Sponsor or his representative shall submit details of compensation provided or paid for clinical trial related injury or death, to the Licensing Authority within <b>30 days</b> of the receipt of the order of the Licensing Authority

### **8. Abbreviations:**

- i. CDSCO : Central Drugs Standard Control Organization
- ii. Co-I : Co-Investigator
- iii. CRF : Case Record Form
- iv. GCP : Good Clinical Practice
- v. ICH : International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
- vi. ICMR : Indian Council of Medical Research
- vii. IEC : Institutional Ethics Committee
- viii. OPD : Out Patient Department
- ix. OTC : Over The Counter
- x. PI : Principal investigator
- xi. SAE : Serious Adverse Event
- xii. SOP : Standard Operating Procedure

**Category** : Study conduct  
**Title** : Serious Adverse Event (SAE) Documentation  
**SOP No.** : D 15/07  
**Date first effective:** 01 Jan 2025      **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, First Floor, New MS Building,  
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

**Reviewer:** Dr. Mahesh Belhekar  
Associate Professor  
*Dr. Mahesh N. Belhekar*  
Associate Professor  
Department of Clinical Pharmacology  
New MS Building, First Floor,  
Seth GS Medical College and KEM Hospital  
Acharya Dande Marg, Parel,  
Mumbai - 400 012, India

*Belh*  
*30/Dec/2024*

Signature with date

**Approved by:** Dr. Nithya Gogtay  
Professor and Head

*N*      *30/12/24*  
**Dr. Nithya Gogtay**  
Professor & Head  
Department of Clinical Pharmacology  
1<sup>st</sup> Floor, MS Building,  
Seth GS Medical College & KEM Hospital,  
Parel, Mumbai - 400 012.

Signature with date